Next Article in Journal
Construction of a miRNA-Based Nomogram Model to Predict the Prognosis of Endometrial Cancer
Previous Article in Journal
A Surgeon That Switched to Unrestricted Kinematic Alignment with Manual Instruments Has a Short Learning Curve and Comparable Resection Accuracy and Outcomes to Those of an Experienced Surgeon
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams

1
Division of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, 80131 Naples, Italy
2
Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, 67100 L’Aquila, Italy
3
Italian Society of Medical and Interventional Radiology (SIRM), SIRM Foundation, 20122 Milan, Italy
4
Medical Oncology Division, Igea SpA, 80013 Napoli, Italy
5
Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy
6
Hepatobiliary Surgical Oncology Division, Istituto Nazionale Tumori IRCCS Fondazione Pascale—IRCCS di Napoli, Via Mariano Semmola, 80131 Naples, Italy
7
Department of Diagnostic Imaging, Area of Cardiovascular and Interventional Imaging, Abruzzo Health Unit 1, 67100 L’Aquila, Italy
8
Emergency and Interventional Radiology, San Salvatore Hospital, 67100 L’Aquila, Italy
9
Division of Radiology, Università degli Studi della Campania Luigi Vanvitelli, 80127 Naples, Italy
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2022, 12(7), 1153; https://doi.org/10.3390/jpm12071153
Submission received: 14 June 2022 / Revised: 14 July 2022 / Accepted: 15 July 2022 / Published: 16 July 2022
(This article belongs to the Section Methodology, Drug and Device Discovery)

Abstract

:
Desmoid tumors (DTs), also known as desmoid fibromatosis or aggressive fibromatosis, are rare, locally invasive, non-metastatic soft tissue tumors. Although histological results represent the gold standard diagnosis, imaging represents the fundamental tool for the diagnosis of these tumors. Although histological analysis represents the gold standard for diagnosis, imaging represents the fundamental tool for the diagnosis of these tumors. DTs represent a challenge for the radiologist, being able to mimic different pathological conditions. A proper diagnosis is required to establish an adequate therapeutic approach. Multimodality imaging, including ultrasound (US), computed tomography (CT) and Magnetic Resonance Imaging (MRI), should be preferred. Different imaging techniques can also guide minimally invasive treatments and monitor their effectiveness. The purpose of this review is to describe the state-of-the-art multidisciplinary imaging of DTs; and its role in patient management.

1. Introduction

Desmoid tumors (DTs), also known as desmoid fibromatosis or aggressive fibromatosis, is an unusual and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. According to the World Health Organization (WHO), DT is a “clonal fibroblastic proliferation that arises in the deep soft tissues and is characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize”, even though it may be multifocal in the same limb or body part [1]. Although histopathological analysis represents the gold standard for diagnosis [1,2,3], imaging represents a necessary tool during the multidisciplinary approach to these tumors since it allows, thanks to the possibility of multimodality assessment (ultrasound (US), computed tomography (CT) and Magnetic Resonance Imaging (MRI)) [4,5,6,7,8,9,10], the detection, localization and evaluation of adjacent structures involvement, to establish a differential diagnosis so as to guide management (surgical or minimal invasive) [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25].
The purpose of this review is to describe state-of-the-art nature of multimodality imaging evaluation, highlighting the advantages and disadvantages of the different techniques in abdominal and extra-abdominal DTs. We assessed their role during the different phases of patient management, including the possibility of guiding interventional radiology treatment.

2. Epidemiology and Histopathology

Desmoid tumors commonly affect individuals between the age of 15 and 60 years, with a peak incidence at 35–40 years and a reported incidence of 2–4 per million population, mainly in women of reproductive age [1,2,3]. The etiopathogenesis of DTs is unclear, although it is believed to be multifactorial [1,2,3]. DT may be sporadic or familial. Trauma, pregnancy and the use of oral contraceptives have been implicated in etiopathogenesis [1,2,3]. Although pregnancy and the use of oral contraceptives have been shown to be associated with the development of DT, the exact role of hormonal influence is not fully understood [1,2,3]. These lesions can involve different types of connective tissues, including muscle, fascia and aponeurosis. The most common sites are the abdominal wall, abdominal mesentery limbs and girdles [1,2,3,26,27,28,29,30,31,32,33]. These lesions can infiltrate the surrounding tissues and organs, spreading across the various floors muscle structures and although they have a low tendency to metastasize, they have a high propensity for local recurrence. Therefore, this tumor has now been classified as an “intermediate, locally aggressive” tumor in the WHO classification of soft tissue tumors [1,2,4].
To date, two different clinical–pathological entities have been identified: sporadic DT and DT associated with adenomatous polyposis coli (APC) gene mutation [1]. Most of these cancers arise as sporadic variants. Sporadic tumors are more frequently extra-abdominal [2,34,35,36,37]. Several studies show that the inherited variant can be seen in 5–16% of patients with familial adenomatosis polyposis (FAP) [1,2,3]. FAP-related DTs lesions are mainly in the abdominal cavity (about 80%), abdominal wall (10–15%) and extra-abdominal (about 5%). [1,2,3] Intra-abdominal DTs are mostly located in the mesentery. These tumors grow slowly, generally increasing by 2 to 9 cm per year, and locally without metastasizing distantly. Despite their benign nature, they can be infiltrative and multifocal, causing significant morbidity and mortality [1,2]. In addition, DT associated with FAP tends to have multifocal lesions, larger and most commonly occurs in younger patients [1,2,3].
It was demonstrated that a third variant known as “wild-type” DT (without CTNNB1 or APC mutations) does not exist and is the result of a diagnostic error (other proliferations of spindle cells that mimic DT) or DT with unrecognized CTNNB1 or APC mutations [1,2,3].
The definitive diagnosis is histopathological with evidence of the proliferation of uniform spindle cells resembling myofibroblasts in the background of abundant collagenous stroma and the vascular network and characterized immunohistochemistry stains positive for nuclear B-catenin, vimentin, cyclooxygenase 2, tyrosine kinase PDGFRb, androgen receptor and estrogen receptor beta but negative for desmin, S-100, h-caldesmon, CD34 and c-KIT [1,2].

3. Clinical Presentation and Treatment

The clinical presentation of DTs is variable and correlates with tumor location [1,2,3].
Generally, DTs have a chronic progression, remaining asymptomatic for a long time and developing into a solid lesion which might present with pain. However, larger lesions and those adjacent to neurovascular structures may be associated with pain and functional impairment [1,2,3]. Desmoid tumor complications correlate to their locally aggressive character, causing compression and/or invasion of the adjacent organs and tissues (Figure 1). Intra-abdominal DTs may determine bleeding, intestinal obstruction, perforation and, infrequently, an abscess [1,2,3].
Most DTs in the abdominal wall and extra-abdominal sites may present as a painless mass. Extra-abdominal DTs (EADTs) localization is more common in the head and neck region, where involvement of the airways or major vessels can present with hoarseness, dyspnea or, in extremely rare cases, be fatal [37,38,39,40,41]. Follow localizations at limbs, presenting as palpable masses, severe pain or muscle contractures and at the thoracic and abdominal wall [42,43,44,45,46,47,48,49,50].
Surgical resection may be more complicated for intra-abdominal DTs compared to extra-abdominal and abdominal wall lesions. In fact, resection may be technically challenging, particularly in patients with FAP. So, surgery has lost its traditional role as a first-line treatment of the disease, and several other treatment methods are being considered [51,52,53,54,55,56,57,58,59,60,61]. In fact, for asymptomatic patients, close observation by serial imaging should be initiated with an interval of 3 to 6 months, given the variable nature of DTs, including the possibility of spontaneous regression. Despite this, primary surgery with negative margins was considered, in the past, the standard of care. However, due to the pattern of infiltrative growth, the scope of resection needed to achieve negative margins could often lead to important function impairments and cosmetic alterations, which are not acceptable in an indolent disease. Furthermore, the efficacy of marginal R1 resections remains unclear. A positive surgical margin was found to be an adverse predictor of worse local control in some series but not in others [3,34]. Several researchers showed that progression-free survival curves were not significantly different based on the microscopic assessment of surgical resection quality (R0 versus R1), although R2 resections resulted in a significantly poorer prognosis [3,34]. Other prognostic factors associated with poor PFS were age younger than 37 years, tumor size larger than 7 cm and extra-abdominal localization, especially tumors found in the distal extremities [3,34]. Based on these data, French [60] and Italian sarcoma groups [11] did not recommend surgery as upfront therapy, except in the case of the patient’s preference. So, increasing attention has been directed toward initial non-operative management, including watchful waiting using nonsteroidal anti-inflammatory drugs (NSAIDs) with or without hormonal manipulation, chemotherapy or radiation therapy [3,11,34,60].
With regard to radiation therapy, this approach should be considered for tumors located at critical sites (such as the head and neck, limb girdles and pelvis), for which surgery would involve functional impairment, or for inoperable, symptomatic/progressive disease that did not respond to other therapeutic approaches, radiotherapy alone could be preferable over other local treatments [3]. Adjuvant radiotherapy is recommended for extremity/limb girdle disease after R1/R2 resection for recurrent disease or following surgery at critical sites (i.e., head and neck), regardless of margins status.
Aggressive chemotherapy should be avoided because it is associated with significant morbidities. However, cytotoxic chemotherapy, non-cytotoxic systemic therapy and targeted therapy have been revealed as part of different treatment regimens [62,63,64,65,66,67,68,69,70,71,72]. Cytotoxic chemotherapy is usually the first treatment option for rapidly growing and symptomatic unresectable or advanced diseases. The most frequently used regimens include methotrexate and vinblastine in combination and an anthracycline-based regimen [3]. Recent progress regarding DT biology and molecular pathways has led to the development of promising novel biological agents. In any case, a multidisciplinary approach is required and is gradually employed, especially in intra-abdominal DTs [62,63,64,65,66,67,68,69,70,71,72]. In addition, recent studies in the literature have shown that EADTs, following a correct surgical excision of the lesion with undamaged surgical margins, have a low rate of local recurrence and distant metastasis. The relationship between age, sex and local recurrence prognosis is controversial. Conversely, tumor size can be considered a possible risk factor for a poor prognosis, as tumors > 5 cm in size have a higher recurrence rate [2,3,4]. Occasionally, surgical management is the only option in complicated patients [73,74,75,76,77,78,79].

4. Imaging

Since the management of DTs mandates a multidisciplinary approach, imaging plays a pivotal role in the detection and assessment of these lesions. In the correct radiological disease management, multimodality imaging, including ultrasound (US), Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), should also be preferred concerning the different phases of DTs approaches [80,81,82,83,84,85,86,87,88,89,90,91,92]. In fact, during radiologist work-up, different moments may be considered: detection and characterization, adjacent structures involvement assessment, treatment response evaluation and surveillance [93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110]. During each of these moments, the different techniques can be associated with and/or follow each other.

5. Ultrasound Assessment

Ultrasound (US) is an inexpensive tool, widely available and safe since it does not use ionizing radiation so that the examination can be repeated several times, even in risk categories such as children and pregnant women [111,112,113,114,115,116]. US plays a limited role mainly in the delineation of mass and lesions involving the abdominal wall, chest wall, breast and extremities. However, due to operator dependence and the poor performance of small intra-abdominal lesions, the necessity for patient collaboration reduces the sensitivity and specificity both in detection and characterization [111,112,113,114,115,116].
On US assessment (Table 1), these lesions show a variable appearance ranging from well-circumscribed to poorly defined infiltrative heterogeneous solid mass with variable echogenicity depending upon the amount of collagen, fibrosis and cellular components within the lesion. Vascularity is variable, as manifested at Color Doppler US or Contrast-enhanced US (CEUS) [80]. DT may be associated with a fascial tail sign, indicating thin linear extension along fascial planes and the staghorn sign from intramuscular fingerlike extensions of the tumor [80]. Sometimes DTs appear as irregular, speculated, hypoechoic masses with Color Doppler flow mimicking malignancy [117,118,119]. US can be used to guide ablation treatment in DT unfit for surgical resection [120]. Radiofrequency ablation (RFA) is the most frequently employed ablation tool, and its success is essentially due to the minimally invasive nature of the treatment with lower complication rates, superior toxicity profiles and often comparable or superior mid- and long-term oncologic outcomes compared to conventional therapies such as surgical procedures or systemic treatments [121,122,123,124,125]. There are few reports on the RFA treatment of DTs with relatively small volumes in superficial tissues, such as the abdominal wall, limbs and trunk [126,127,128,129]. In these cases, US is a promising tool for planning, targeting, monitoring, intra-procedural modification and assessing treatment response, including technical success, treatment efficacy and complications [130,131,132,133,134].
To the best of our knowledge, one study described CEUS appearance in abdominal DT [135], with the early enhancement of the contrast agent and very long wash-out, a typical pattern of benign lesions probably due to the presence of fibrotic tissue [135]. Xu et al. described CEUS appearance in 19 cases of superficial DF: the tumors were hyperenhanced, with an enhanced pattern of rapid wash-in and slow wash-out [136].
Table 1. Imaging features of abdominal and extra-abdominal DTs and advantages and weaknesses of diagnostic tools.
Table 1. Imaging features of abdominal and extra-abdominal DTs and advantages and weaknesses of diagnostic tools.
Desmoid TumorUSCTMRI
Abdominal features
[80]
Variable appearance ranging from well-circumscribed to poorly defined infiltrative heterogeneous solid mass with variable echogenicity. Vascularity is variable.
At CEUS, early enhancement of the contrast agent and a very long washout
CT findings of intra-abdominal lesions are determined by the amount of collagen and myxoid tissue; therefore, the myxoid component of the tumor tends to be hypodense compared to skeletal muscle, while the collagen and fibrotic component may be isodense or hyperdense. After intravenous contrast administration, the enhancement is mild to moderateHeterogeneous pattern, with signal iso- to hyperintense to skeletal muscle on T2-weighted images and isointense to muscle on T1-weighted images. Decreased signal intensity on T2-weighted images most likely results from dense collagen and hypocellularity; conversely, increased T2 signal intensity reflects a high content of spindle cells.
DTs commonly (90%) show moderate to intense contrast enhancement, especially in the more cellular and less fibrotic regions.
Extra-abdominal Features
[137]
Variable appearance from well-circumscribed to poorly defined infiltrative heterogeneous solid mass with variable echogenicity. Vascularity is variable.
At CEUS, early enhancement of the contrast agent and a very long washout
Slightly lower density, a higher degree of enhancement and unclear boundariesExtra-abdominal DTs typically occur in the intermuscular location along deep fascia and may show a thin rim of surrounding fat (split fat sign), linear enhancing extension along the fascial planes, and feathery margins resembling a flame (flame sign).
AdvantagesInexpensive;
widely available;
safe
[111,112,113,114,115,116]
Requires high spatial resolution to obtain sufficient anatomical detail for the detection of deep lesions and for targeting interventional procedures
[80]
Multiparametric approach;
the exceptional contrast resolution;
functional assessment
[138,139,140,141,142,143]
WeaknessOperator dependence;
poor performance for small intra-abdominal lesions; patient’s collaboration
[111,112,113,114,115,116]
Radiation exposure
[97]
Long examination and interpretation time;
high costs
[97]

6. Computed Tomography Assessment

CT has a dual approach: diagnostic and therapeutic. The sensitive advantage of the use of CT is to have a high spatial resolution and obtain sufficient anatomical detail for the detection of deep lesions and for targeting interventional procedures [144,145,146]. A recent technique, dual-energy CT (DECT), was established to increase tumor detection [147,148]. DECT, which is founded on the instantaneous acquisition of two image datasets at different energy levels, can produce virtual monochromatic images (VMIs) [149]. Additionally, thanks to DECT, radiation and contrast media doses are lower compared to conventional CT, which is mainly beneficial for patient surveillance [149].
CT is commonly used to image DTs (Table 1 and Table 2), particularly for intra-abdominal localizations for diagnosis and follow-up, as well as in preoperative assessment to identify the relationship of the tumor with adjacent neurovascular structures and organs. CT can provide critical information required for treatment planning. In addition, complications such as bowel obstruction, bowel ischemia and hydronephrosis are readily identified on CT. However, CT contributes up to 65% of medically induced radiation exposure, and this is a main critical point that should be considered during follow-up in young patients [97]. In addition, the administration of intravenous contrast media (CM) is an integral element of many CT examination protocols [97]. However, CM administration is also accompanied by a potential risk for adverse reactions, in particular, allergic reactions and contrast-induced nephropathy. Therefore, CM administration should be scrutinized, and the lowest adequate dose should be used [97].
The CT findings of intra-abdominal lesions are determined by the amount of collagen and myxoid tissue; therefore, the myxoid component of the tumor tends to be hypodense compared to skeletal muscle, while the collagen and fibrotic component may be isodense or hyperdense. After intravenous contrast administration, enhancement is mild to moderate (Figure 2) [80]. Necrosis and calcifications are extremely rare.
Shi et al. evaluated the imaging features in 13 patients with desmoid fibroma of the extremities, finding that the tumors showed a lower density (69.23%), a higher degree of enhancement (61.54%) and unclear boundaries (84.62%) (Figure 3); a CT value < 50 Hu was encountered in 53.85% of lesions, and the enhancement was uneven in 53.85% of cases [137].
To the best of our knowledge, no one study described the role of DECT in DTs.
As in US, CT also plays a pivotal role in guiding ablative treatment. In particular, CT-guided cryoablation is safe, effective and offers some important advantages. First, it presents the possibility of treating even large and multiple lesions in one session, creating a large area of ablation with low risks of spreading the pathological cells. Second, the technique is minimally invasive and requires low hospitalization times and mild anesthesia. Third, the functional recovery is satisfyingly immediate. Fourth, the procedure can be repeated with no risks for the patient in case of partial treatment [150,151,152].

7. Magnetic Resonance Imaging Assessment

Thanks to the multiparametric approach, the exceptional contrast resolution and the possibility to exploit several advanced sequences, magnetic resonance imaging is the diagnostic gold standard for the study, characterization and follow-up of extra-abdominal DTs, with a pivotal role for intra-abdominal ones [138,139,140,141,142,143]. Most advantages are evident in particular extra-abdominal lesions occurring in the extremities, head and neck, abdominal and chest wall and in lesions at mesenteric localization in patients allergic to contrast agents or in young patients to reduce radiation exposure [1,7,21]. The signal intensity of MRI reflects the proportion of collagen fibers, spindle cells and extracellular matrix present and varies with imaging sequences. The commonly observed MR imaging appearance is a heterogeneous pattern, with signal iso- to hyperintense in the skeletal muscle on T2-weighted images and isointense in the muscle on T1-weighted images. Decreased signal intensity on T2-weighted images most likely results from dense collagen and hypocellularity; conversely, increased T2 signal intensity reflects a high content of spindle cells. DTs commonly (90%) show moderate to intense contrast enhancement (Figure 4 and Figure 5), especially in the more cellular and less fibrotic regions; however, areas of non-contrast enhancement related to necrosis may rarely be present (Table 1 and Table 2) [80].
Some characteristic but not specific findings of DTs on MRI have been identified. Low-signal-intensity non-enhancing linear bands in all sequences, known as the band sign, are present in 60% to 90% of DTs and can be seen in other benign (giant cell tumor of the tendon sheath) and malignant (myxofibrosarcoma and malignant fibrous histiocytoma), likely corresponding to the dense collagenous stroma often found at histologic examination [80]. Extra-abdominal DTs typically occur in the intermuscular location along deep fascia (Figure 6) and may show a thin rim of surrounding fat (split fat sign) (83% of DTs), linear enhancing extension along the fascial planes and feathery margins resembling a flame (flame sign) [80].
Beyond information on morphology, several MRI sequences can be used to obtain functional, ultrastructural information on tissue and deepen the diagnosis.
Using DWI imaging, the DWI signal and the ADC values reflect the cellularity of the tissues, so even if there are no normal cutoff values, DWI can characterize the biological activity of the tissues [153,154,155,156,157,158,159,160]. In the study of musculoskeletal soft tissue tumors, this means that, as a general rule, benign tumors with a low degree of biological activity will have a loss of ADC signal as the b values increase, while malignant tumors (in which the water has greater restriction in movement) will show high intensity at high b values [161,162]. The mean ADC of DTs was found to be significantly higher than that of malignant soft tissue tumors without overlap in the minimum ADC values [163]. DWI has also proved very useful in the assessment of treatment response [66,96]. Similarly, the evaluation of enhancement patterns can be challenging, as both granulation and scar tissues (aspecific tissue changes after chemo/radiotherapy) are enhanced after contrast administration, and the differentiation from the viable tumor is not always direct. DWI was demonstrated to improve this discrimination earlier than conventional imaging, as solid tumors are characterized by high cellularity with intact cell membranes, while tissues after cytotoxic treatment show lower cellularity and membrane damage. DWI also implements standard morphological sequences in the evaluation of postsurgical follow-up, aiding in detecting residual/recurrent tumor tissue [42,94].
Dynamic perfusion MRI is another functional imaging technique often used to evaluate tumors, mainly to depict the early intravascular and interstitial distribution of gadolinium [164,165,166,167,168,169,170,171,172]. In DTs, despite considerable variability, a time-intensity curve characterized by rapid early enhancement followed by a plateau was described [80]. However, despite the characteristic imaging results of DTs on MR imaging, a biopsy is required for histological characterization. In addition, the histological characteristics of DTs can vary over time and are reflected in MR imaging and are useful as a support in evaluating response to treatment [80].
MRI can guide ablative treatment as US and CT. High-intensity focused ultrasound (HIFU) ablation is a noninvasive treatment that has been successfully used for the treatment of various solid tumors [17]. In the past decade, several studies have been reported, suggesting the safety and efficacy of HIFU ablation for the treatment of DTs [173,174,175,176,177,178,179]. HIFU uses nonionizing radiation ultrasound as the physical therapy factor. Therefore, it not only has the potential of being a repeatable treatment but also has the potential to safely ablate more tumor tissue. Although a few studies have reported the safety and efficacy of HIFU in DTs, the sample size was too small. In addition, DTs can occur in any part of the body, including the extra-abdominal, abdominal wall and intra-abdominal types. The safety and efficacy of HIFU ablation for different types of DTs also should be assessed [180].
The critical weakness of MR assessment is related to the long examination and interpretation time, as well as higher costs, which still represent barriers to MRI use [97]. Abbreviated MRI protocols have emerged as an alternative to standard MRI protocols. These abbreviated protocols seek to reduce longer MRI protocols by eliminating unnecessary or redundant sequences that negatively affect the cost, examination time, patient comfort and image interpretation time [97].

8. Differential Diagnoses

Regarding the abdominal wall, several pathological processes can cause wall lesions to comprise infection, hematoma, endometriosis and neoplasm [181,182]. Regarding mesenteric DT, these entities typically occur in FAP patients. However, in FAP patients with colorectal cancer, it is possible to find mesenteric metastases that mimic DT. In addition, other pathological entities should be considered in the differential diagnoses, including gastrointestinal stromal tumor (Figure 7), lymphoma (Figure 8), neuroendocrine tumor, carcinoma (Figure 9) and retractile sclerosing mesenteritis [2]. In this context, clinical history and imaging features could be helpful in lesion characterization.
Desmoid tumors in FAP patients are characterized considering clinical data, surgical history and imaging studies. CT and MRI allow us to characterize the lesion and to determine the relationship between lesions and surrounding organs for proper treatment planning. During CT study, the lesion density is uniform with uniform enhancement during the contrast study [80,137]. These features are not typically for gastrointestinal stromal tumors, lymphoma, neuroendocrine tumors and/or carcinoma, which show inhomogeneous density due to necrosis or for hormonal mesenteric reaction [80,137]. In addition, DTs have several typical features on MRI evaluation, such as a star shape and extension into the fascial planes and fat tissue in a sunburst-like form, with homogeneous signal isointense in T1-W and hyperintense in T2-W [80].
Regarding extra-abdominal DTs, several soft tissue lesions (melanoma metastases, primitive soft sarcoma, etc.), occurring in extremities, head and neck and trunk, may mimic these entities. During CT studies, DTs of the extremities show a low density, mild enhancement and unclear boundary [137]. In MRI studies, typical features are a round or fusiform shape, unclear boundaries, uniform signals, uneven enhancement, “tree root” or “claw” infiltration and invasion of the neurovascular bundles [137]. Conversely to them, malignant soft tissue tumors show inhomogeneous T1-W and T2-W signals, and the T2 signal intensity is higher than fat signal, with calcifications or cystic necrosis [183,184]. Therefore, CT and MRI studies allow us to identify typical extremities’ DTs features, although MRI provides an objective basis for the diagnosis. Additionally, MRI has a higher soft tissue contrast with clear advantages in the soft tissue tumors assessment (especially in the extremities or head and neck). It is also suitable for younger patients in whom the use of ionizing radiation should be avoided or who are allergic to iodine contrast agents. However, CT and MRI can be combined to optimize the diagnostic accuracy, as well as to reduce the incidence of missed diagnosis or misdiagnosis [183].
So, CT or MRI scans can not only help for diagnosis but also in determining the relationship between tumors and the surrounding organs to obtain proper pre-treatment planning. Otherwise, although US assessment is safe since it does not use ionizing radiation so that the examination can be repeated several times [111,112,113,114,115,116], it plays a limited role in the delineation of mass and lesions involving the abdominal wall, chest wall, breast and extremities. However, due to operator dependence and the poor performance of small intra-abdominal lesions, there is a necessity for patient collaboration to reduce the sensitivity and specificity both in the detection and characterization of these tumors.
Although imaging assessment could help characterization, a definitive diagnosis requires histopathological confirmation [2]. Pathology is the gold standard for the diagnosis of DTs. Histological examination reveals paucicellular proliferation of fibroblasts and myofibroblasts in a dense collagenous background, spindle cells with small and regular nuclei, pale eosinophilic cytoplasm and acellular central areas with increasing cellularity towards the periphery. Immunohistochemistry shows the cells are b-catenin, vimentin, Ki-67, SMA, CD68 and CD34 positive, which can assist with the diagnosis [2].

9. Conclusions

Desmoid tumors represent a challenge for the radiologist, being able to mimic different pathological conditions. A proper diagnosis is required to establish the proper therapeutic approach in relation to the location, clinic and evolution of the disease. Imaging plays a pivotal role in the detection and assessment of these lesions. In the correct radiological disease management, multimodality imaging, including US, CT and MRI, should be preferred. Furthermore, in relation to the different phases of DTs approaches, detection and characterization, adjacent structures involvement assessment, treatment response evaluation and surveillance should also be considered. These different imaging techniques can also guide minimally invasive treatments and monitor their effectiveness.
Regarding differential diagnoses, although imaging assessment could aid characterization, a definitive diagnosis requires histopathological confirmation.

Author Contributions

I.S., F.B., R.F., C.C., S.V.S., R.P., C.M., P.P., F.A., C.P., A.B. (Andrea Belli), R.G., F.G., A.B. (Antonio Barile), F.I., A.P. and V.G. contributed equally to the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received funding from the Ministry of Health—Current Research 2022.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available at https://zenodo.org/record/6805439#.YsZ_t4RBy3A (accessed on 13 June 2022).

Acknowledgments

The authors are grateful to Alessandra Trocino, librarian at the National Cancer Institute of Naples, Italy.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur. J. Cancer 2020, 127, 96–107. [Google Scholar] [CrossRef] [Green Version]
  2. Ganeshan, D.; Amini, B.; Nikolaidis, P.; Assing, M.; Vikram, R. Current Update on Desmoid Fibromatosis. J. Comput. Assist. Tomogr. 2019, 43, 29–38. [Google Scholar] [CrossRef] [PubMed]
  3. Penel, N.; Chibon, F.; Salas, S. Adult desmoid tumors: Biology, management and ongoing trials. Curr. Opin. Oncol. 2017, 29, 268–274. [Google Scholar] [CrossRef] [PubMed]
  4. Granata, V.; Grassi, R.; Fusco, R.; Setola, S.V.; Belli, A.; Ottaiano, A.; Nasti, G.; La Porta, M.; Danti, G.; Cappabianca, S.; et al. Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: How radiologist should assess MR features. Radiol. Med. 2021, 126, 1584–1600. [Google Scholar] [CrossRef] [PubMed]
  5. Hussein, M.A.M.; Cafarelli, F.P.; Paparella, M.T.; Rennie, W.J.; Guglielmi, G. Phosphaturic mesenchymal tumors: Radiological aspects and suggested imaging pathway. Radiol. Med. 2021, 126, 1609–1618. [Google Scholar] [CrossRef] [PubMed]
  6. Danti, G.; Flammia, F.; Matteuzzi, B.; Cozzi, D.; Berti, V.; Grazzini, G.; Pradella, S.; Recchia, L.; Brunese, L.; Miele, V. Gastrointestinal neuroendocrine neoplasms (GI-NENs): Hot topics in morphological, functional, and prognostic imaging. Radiol. Med. 2021, 126, 1497–1507. [Google Scholar] [CrossRef]
  7. Karmazanovsky, G.; Gruzdev, I.; Tikhonova, V.; Kondratyev, E.; Revishvili, A. Computed tomography-based radiomics approach in pancreatic tumors characterization. Radiol. Med. 2021, 126, 1388–1395. [Google Scholar] [CrossRef]
  8. Fusco, R.; Petrillo, M.; Granata, V.; Filice, S.; Sansone, M.; Catalano, O.; Petrillo, A. Magnetic resonance imaging evaluation in neoadjuvant therapy of locally advanced rectal cancer: A systematic review. Radiol. Oncol. 2017, 51, 252–262. [Google Scholar] [CrossRef] [PubMed]
  9. Fusco, R.; Sansone, M.; Granata, V.; Setola, S.V.; Petrillo, A.; Fusco, R.; Sansone, M.; Granata, V.; Setola, S.V.; Petrillo, A. A systematic review on multiparametric MR imaging in prostate cancer detection. Infect. Agents Cancer 2017, 12, 57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Granata, V.; Fusco, R.; Avallone, A.; Filice, F.; Tatangelo, F.; Piccirillo, M.; Grassi, R.; Izzo, F.; Petrillo, A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget 2017, 8, 51224–51237. [Google Scholar] [CrossRef] [Green Version]
  11. Linee Guida 2020 Per Sarcomi Dei Tessuti Molli e GIST. Available online: https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_Sarcomi.pdf (accessed on 12 June 2022).
  12. Barabino, M.; Gurgitano, M.; Fochesato, C.; Angileri, S.A.; Franceschelli, G.; Santambrogio, R.; Mariani, N.M.; Opocher, E.; Carrafiello, G. LI-RADS to categorize liver nodules in patients at risk of HCC: Tool or a gadget in daily practice? Radiol. Med. 2021, 126, 5–13. [Google Scholar] [CrossRef]
  13. Granata, V.; Fusco, R.; Filice, S.; Catalano, O.; Piccirillo, M.; Palaia, R.; Izzo, F.; Petrillo, A. The current role and future prospectives of functional parameters by diffusion weighted imaging in the assessment of histologic grade of HCC. Infect. Agents Cancer 2018, 13, 23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Orlacchio, A.; Chegai, F.; Roma, S.; Merolla, S.; Bosa, A.; Francioso, S. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): Long-term results from a single-center 137-patient cohort prospective study. Radiol. Med. 2020, 125, 98–106. [Google Scholar] [CrossRef]
  15. Granata, V.; Fusco, R.; Avallone, A.; Catalano, O.; Filice, F.; Leongito, M.; Palaia, R.; Izzo, F.; Petrillo, A. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: An overview and update. Infect. Agents Cancer 2017, 12, 23. [Google Scholar] [CrossRef] [Green Version]
  16. De Filippo, M.; Ziglioli, F.; Russo, U.; Pagano, P.; Brunese, L.; Bertelli, E.; Pagnini, F.; Maestroni, U. Radiofrequency ablation (RFA) of T1a renal cancer with externally cooled multitined expandable electrodes. Radiol. Med. 2020, 125, 790–797. [Google Scholar] [CrossRef] [PubMed]
  17. Arrigoni, F.; Bruno, F.; Gianneramo, C.; Palumbo, P.; Zugaro, L.; Zoccali, C.; Barile, A.; Masciocchi, C. Evolution of the imaging features of osteoid osteoma treated with RFA or MRgFUS during a long-term follow-up: A pictorial review with clinical correlations. Radiol. Med. 2020, 125, 578–584. [Google Scholar] [CrossRef] [PubMed]
  18. Granata, V.; Grassi, R.; Fusco, R.; Setola, S.V.; Palaia, R.; Belli, A.; Miele, V.; Brunese, L.; Petrillo, A.; Izzo, F. Assessment of Ablation Therapy in Pancreatic Cancer: The Radiologist’s Challenge. Front. Oncol. 2020, 10, 560952. [Google Scholar] [CrossRef]
  19. Granata, V.; Grassi, R.; Fusco, R.; Belli, A.; Palaia, R.; Carrafiello, G.; Miele, V.; Petrillo, A.; Izzo, F. Local ablation of pancreatic tumors: State of the art and future perspectives. World J. Gastroenterol. 2021, 27, 3413–3428. [Google Scholar] [CrossRef]
  20. Trombadori, C.M.L.; D’Angelo, A.; Ferrara, F.; Santoro, A.; Belli, P.; Manfredi, R. Radial Scar: A management dilemma. Radiol. Med. 2021, 126, 774–785. [Google Scholar] [CrossRef]
  21. Argalia, G.; Tarantino, G.; Ventura, C.; Campioni, D.; Tagliati, C.; Guardati, P.; Kostandini, A.; Marzioni, M.; Giuseppetti, G.M.; Giovagnoni, A. Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. Radiol. Med. 2021, 126, 894–899. [Google Scholar] [CrossRef]
  22. Granata, V.; Petrillo, M.; Fusco, R.; Setola, S.V.; De Lutio Di Castelguidone, E.; Catalano, O.; Piccirillo, M.; Albino, V.; Izzo, F.; Petrillo, A. Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute. Gastroenterol. Res. Pract. 2013, 2013, 469097. [Google Scholar] [CrossRef]
  23. Ierardi, A.M.; Gaibazzi, N.; Tuttolomondo, D.; Fusco, S.; La Mura, V.; Peyvandi, F.; Aliberti, S.; Blasi, F.; Cozzi, D.; Carrafiello, G.; et al. Deep vein thrombosis in COVID-19 patients in general wards: Prevalence and association with clinical and laboratory variables. Radiol. Med. 2021, 126, 722–728. [Google Scholar] [CrossRef] [PubMed]
  24. Zhu, Q.; Chen, D.; Zhou, C.; Luo, M.; Huang, W.; Huang, J.; Huang, J.; Chen, Y. Percutaneous endovenous intervention without vena cava filter for acute proximal deep vein thrombosis secondary to iliac vein compression syndrome: Preliminary outcomes. Radiol. Med. 2021, 126, 729–736. [Google Scholar] [CrossRef] [PubMed]
  25. Trimboli, P.; Castellana, M.; Virili, C.; Havre, R.F.; Bini, F.; Marinozzi, F.; D’Ambrosio, F.; Giorgino, F.; Giovanella, L.; Prosch, H.; et al. Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: A systematic review and meta-analysis using histological standard of reference. Radiol. Med. 2020, 125, 406–415. [Google Scholar] [CrossRef]
  26. Zhou, M.Y.; Bui, N.Q.; Charville, G.W.; Ghanouni, P.; Ganjoo, K.N. Current management and recent progress in desmoid tumors. Cancer Treat. Res. Commun. 2022, 31, 100562. [Google Scholar] [CrossRef]
  27. Bilreiro, C.; Soler, J.C.; Ayuso, J.R.; Caseiro-Alves, F.; Ayuso, C. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma. Radiol. Med. 2021, 126, 1379–1387. [Google Scholar] [CrossRef]
  28. Zheng, Q.; Liu, B.; Zhou, Y.; Liu, D. Prognostic factors of abdominal desmoid tumor fibromatosis after surgery: A retrospective study of 52 patients. Asian J. Surg. 2022; ahead of print. [Google Scholar] [CrossRef]
  29. Minami, Y.; Matsumoto, S.; Ae, K.; Tanizawa, T.; Hayakawa, K.; Saito, M.; Kurosawa, N. The Clinical Features of Multicentric Extra-abdominal Desmoid Tumors. Cancer Diagn. Progn. 2021, 1, 339–343. [Google Scholar] [CrossRef]
  30. Qin, H.; Que, Q.; Lin, P.; Li, X.; Wang, X.-R.; He, Y.; Chen, J.-Q.; Yang, H. Magnetic resonance imaging (MRI) radiomics of papillary thyroid cancer (PTC): A comparison of predictive performance of multiple classifiers modeling to identify cervical lymph node metastases before surgery. Radiol. Med. 2021, 126, 1312–1327. [Google Scholar] [CrossRef]
  31. Tsuchihashi, K.; Yamaguchi, K.; Taguchi, R.; Kohashi, K.; Ijichi, K.; Okumura, Y.; Nakano, M.; Ohno, A.; Hioki, T.; Shimokawa, H.; et al. Spontaneous Regression of Metachronous Intra-Abdominal Desmoid Tumor in a Patient with Familial Adenomatous Polyposis. Case Rep. Oncol. 2022, 15, 71–77. [Google Scholar] [CrossRef]
  32. Negroni, D.; Cassarà, A.; Trisoglio, A.; Soligo, E.; Berardo, S.; Carriero, A.; Stecco, A. Learning curves in radiological reporting of whole-body MRI in plasma cell disease: A retrospective study. Radiol. Med. 2021, 126, 1451–1459. [Google Scholar] [CrossRef]
  33. Schoelles, K.; Federmann, Y.; Kurz, P.; Selt, F.; Schupp, W.; Lagrèze, W.; Lang, S.; Auw-Haedrich, C. Aggressive fibromatosis in a child: A diagnostic challenge. Pathology, 2022; ahead of print. [Google Scholar] [CrossRef]
  34. Penel, N.; Bonvalot, S.; Bimbai, A.-M.; Meurgey, A.; Le Loarer, F.; Salas, S.; Piperno-Neumann, S.; Chevreau, C.; Boudou-Rouquette, P.; Dubray-Longeras, P.; et al. Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. Clin. Cancer Res. 2022; ahead of print. [Google Scholar] [CrossRef]
  35. Damiani, G.; Mikhael, R.; Tzanis, D.; El Zein, S.; Bonvalot, S. Desmoid Tumors Arising on the Mesenteric Surgical Scar of Abdominal Sarcomas. Cureus 2022, 14, e21727. [Google Scholar] [CrossRef]
  36. Colombo, C.; Fiore, M.; Grignani, G.; Tolomeo, F.; Merlini, A.; Palassini, E.; Collini, P.; Stacchiotti, S.; Casali, P.G.; Perrone, F.; et al. A prospective observational study of Active surveillance in primary desmoid fibromatosis. Clin. Cancer Res. 2022; ahead of print. [Google Scholar] [CrossRef]
  37. Mastoraki, A.; Schizas, D.; Vassiliu, S.; Saliaris, K.; Giagkos, G.-C.; Theochari, M.; Vergadis, C.; Tolia, M.; Vassiliu, P.; Felekouras, E. Evaluation of diagnostic algorithm and therapeutic interventions for intra-abdominal desmoid tumors. Surg. Oncol. 2022, 41, 101724. [Google Scholar] [CrossRef] [PubMed]
  38. Coskun, H.S.; Erdogan, F.; Cinka, H.; Dabak, N. Extra-abdominal desmoid fibromatosis: An evaluation of clinical factors affecting local recurrence rates. Acta Orthop. Traumatol. Turc. 2021, 55, 547–551. [Google Scholar] [CrossRef] [PubMed]
  39. Schlag, H.; Neuhoff, J.; Castein, J.; Hoffmann, C.; Kandziora, F. Sporadic desmoid fibromatosis of the neck after dorsal spondylodesis of the cervical spine. Surg. Neurol. Int. 2022, 13, 64. [Google Scholar] [CrossRef] [PubMed]
  40. Lloyd, N.; Kopel, J.; Awasthi, S.; Cordero, J. Case report of recurrent fibromatosis with laryngeal involvement: Treatment based on network analyses of NGS data. Mol. Clin. Oncol. 2022, 16, 73. [Google Scholar] [CrossRef]
  41. Nosé, V.; Lazar, A.J. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Familial Tumor Syndromes. Head Neck Pathol. 2022, 16, 143–157. [Google Scholar] [CrossRef]
  42. Bruno, F.; Arrigoni, F.; Mariani, S.; Splendiani, A.; Di Cesare, E.; Masciocchi, C.; Barile, A. Advanced magnetic resonance imaging (MRI) of soft tissue tumors: Techniques and applications. Radiol. Med. 2019, 124, 243–252. [Google Scholar] [CrossRef]
  43. Liu, D.; Perera, W.; Schlicht, S.; Choong, P.; Slavin, J.; Pianta, M. Musculoskeletal desmoid tumours: Diagnostic imaging appearances. J. Med. Imaging Radiat. Oncol. 2015, 59, 461–467. [Google Scholar] [CrossRef]
  44. Liu, D.; Perera, W.; Schlicht, S.; Choong, P.; Slavin, J.; Pianta, M. Musculoskeletal desmoid tumours: Pre- and post-treatment radiological appearances. J. Med Imaging Radiat. Oncol. 2015, 59, 480–485. [Google Scholar] [CrossRef] [Green Version]
  45. McDonald, E.S.; Yi, E.S.; Wenger, D.E. Best cases from the AFIP: Extraabdominal desmoid-type fibromatosis. Radiographics 2008, 28, 901–906. [Google Scholar] [CrossRef] [Green Version]
  46. Eastley, N.; McCulloch, T.; Esler, C.; Hennig, I.; Fairbairn, J.; Gronchi, A.; Ashford, R. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. Eur. J. Surg. Oncol. (EJSO) 2016, 42, 1071–1083. [Google Scholar] [CrossRef] [PubMed]
  47. Guglielmi, G.; Cifaratti, A.; Scalzo, G.; Magarelli, N. Imaging of superficial and deep fibromatosis. Radiol. Med. 2009, 114, 1292–1307. [Google Scholar] [CrossRef] [PubMed]
  48. Chianca, V.; Albano, D.; Messina, C.; Vincenzo, G.; Rizzo, S.; Del Grande, F.; Sconfienza, L.M. An update in musculoskeletal tumors: From quantitative imaging to radiomics. Radiol. Med. 2021, 126, 1095–1105. [Google Scholar] [CrossRef]
  49. Cellina, M.; Gibelli, D.; Martinenghi, C.; Giardini, D.; Soresina, M.; Menozzi, A.; Oliva, G.; Carrafiello, G. Non-contrast magnetic resonance lymphography (NCMRL) in cancer-related secondary lymphedema: Acquisition technique and imaging findings. Radiol. Med. 2021, 126, 1477–1486. [Google Scholar] [CrossRef] [PubMed]
  50. Brillantino, A.; Iacobellis, F.; Reginelli, A.; Renzi, A.; Grassi, R. Three-dimensional endoanal ultrasound should be considered as first-line diagnostic tool in the preoperative work-up for perianal fistulas. Radiol. Med. 2020, 125, 155–156. [Google Scholar] [CrossRef] [PubMed]
  51. Nathenson, M.J.; Hu, J.; Ratan, R.; Somaiah, N.; Hsu, R.; DeMaria, P.J.; Catoe, H.W.; Pang, A.; Subhawong, T.K.; Amini, B.; et al. Systemic chemotherapies retain anti-tumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: A multi-institutional retrospective study. Clin. Cancer Res. 2022; ahead of print. [Google Scholar]
  52. Cildag, M.B.; Gok, M.; Abdullayev, O. Pre-procedural shear wave elastography on prediction of hemorrhage after percutaneous real-time ultrasound-guided renal biopsy. Radiol. Med. 2020, 125, 784–789. [Google Scholar] [CrossRef] [PubMed]
  53. Di Serafino, M.; Notaro, M.; Rea, G.; Iacobellis, F.; Delli Paoli, V.; Acampora, C.; Vallone, G. The lung ultrasound: Facts or artifacts? In the era of COVID-19 outbreak. Radiol. Med. 2020, 125, 738–753. [Google Scholar] [CrossRef] [PubMed]
  54. Tsukamoto, S.; Takahama, T.; Mavrogenis, A.F.; Tanaka, Y.; Errani, C. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: A systematic review. Musculoskelet. Surg. 2022; ahead of print. [Google Scholar] [CrossRef]
  55. Laurelli, G.; Falcone, F.; Gallo, M.S.; Scala, F.; Losito, S.; Granata, V.; Cascella, M.; Greggi, S. Long-Term Oncologic and Reproductive Outcomes in Young Women with Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update. Int. J. Gynecol. Cancer 2016, 26, 1650–1657. [Google Scholar] [CrossRef]
  56. Johns, M.S.; Merritt, W.T.; Rhodes, L.; Ford, C.N.; Thompson, M.; Lee, W.M.; Sheldon, Y.; Petrelli, N.J.; Tiesi, G.J. A cost analysis of sorafenib for desmoid tumors. J. Oncol. Pharm. Pr. 2022; ahead of print. [Google Scholar] [CrossRef]
  57. Wang, J.; Li, H.; Wang, H.; Li, Q.; Bai, X.; Lv, H.; Nie, C.; Chen, B.; Xu, W.; Tu, S.; et al. Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review. Front. Oncol. 2022, 11, 830672. [Google Scholar] [CrossRef]
  58. Frongillo, E.; Gaudioso, G.; Feragalli, B. Ultrasound and interstitial lung disease: Use and limitations. Radiol. Med. 2020, 125, 66–67. [Google Scholar] [CrossRef]
  59. Hu, S.; Zhang, H.; Sun, Z.; Ge, Y.; Li, J.; Yu, C.; Deng, Z.; Dou, W.; Wang, X. Preoperative assessment of extrathyroidal extension of papillary thyroid carcinomas by ultrasound and magnetic resonance imaging: A comparative study. Radiol. Med. 2020, 125, 870–876. [Google Scholar] [CrossRef] [PubMed]
  60. Penel, N.; Bonvalot, S.; Minard, V.; Orbach, D.; Gouin, F.; Corradini, N.; Brahmi, M.; Marec-Bérard, P.; Briand, S.; Gaspar, N.; et al. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. Ann. Oncol. 2020, 31, 965–966. [Google Scholar] [CrossRef] [PubMed]
  61. Albano, D.; Bonifacini, C.; Zannoni, S.; Bernareggi, S.; Messina, C.; Galia, M.; Sconfienza, L.M. Plantar forefoot pain: Ultrasound findings before and after treatment with custom-made foot orthoses. Radiol. Med. 2021, 126, 963–970. [Google Scholar] [CrossRef] [PubMed]
  62. Mo, S.; Chen, J.; Zhang, R.; Yang, C.; Wang, T.; Chen, L.; Chen, W. High-Intensity Focused Ultrasound Ablation for Postoperative Recurrent Desmoid Tumors: Preliminary Results. Ultrasound Med. Biol. 2022, 48, 638–645. [Google Scholar] [CrossRef] [PubMed]
  63. Kwon, J.; Lee, J.H.; Lee, Y.H.; Lee, J.; Ahn, J.-H.; Kim, S.H.; Kim, S.H.; Kim, T.I.; Yun, K.-H.; Park, Y.S.; et al. Whole-genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. Cancer Res. Treat. 2022; ahead of print. [Google Scholar] [CrossRef]
  64. Li, X.; Zhang, H.; Chen, L.-Q. Robot-assisted thoracoscopic transdiaphragmatic resection of an infradiaphragmatic desmoid-type fibromatosis. Asian J. Surg. 2022, 45, 976–977. [Google Scholar] [CrossRef]
  65. Vora, B.M.K.; Munk, P.L.; Somasundaram, N.; Ouellette, H.A.; Mallinson, P.I.; Sheikh, A.; Kadir, H.A.; Tan, T.J.; Yan, Y.Y. Cryotherapy in extra-abdominal desmoid tumors: A systematic review and meta-analysis. PLoS ONE 2021, 16, e0261657. [Google Scholar] [CrossRef]
  66. Granata, V.; Fusco, R.; Setola, S.V.; Piccirillo, M.; Leongito, M.; Palaia, R.; Granata, F.; Lastoria, S.; Izzo, F.; Petrillo, A. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J. Gastroenterol. 2017, 23, 4767–4778. [Google Scholar] [CrossRef]
  67. Ossola, C.; Curti, M.; Calvi, M.; Tack, S.; Mazzoni, S.; Genesio, L.; Venturini, M.; Genovese, E.A. Role of ultrasound and magnetic resonance imaging in the prognosis and classification of muscle injuries in professional football players: Correlation between imaging and return to sport time. Radiol. Med. 2021, 126, 1460–1467. [Google Scholar] [CrossRef]
  68. Emori, M.; Matsumoto, Y.; Murahashi, Y.; Yoshida, M.; Nishida, Y. Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: A systematic review. Nagoya J. Med. Sci. 2021, 83, 673–681. [Google Scholar] [CrossRef]
  69. Ceravolo, I.; Barchetti, G.; Biraschi, F.; Gerace, C.; Pampana, E.; Pingi, A.; Stasolla, A. Early stage glioblastoma: Retrospective multicentric analysis of clinical and radiological features. Radiol. Med. 2021, 126, 1468–1476. [Google Scholar] [CrossRef] [PubMed]
  70. Refai, M.; Andolfi, M.; Barbisan, F.; Roncon, A.; Guiducci, G.M.; Xiumè, F.; Paci, E. Computed tomography-guided microcoil placement for localizing small pulmonary nodules before uniportal video-assisted thoracoscopic resection. Radiol. Med. 2020, 125, 24–30. [Google Scholar] [CrossRef] [PubMed]
  71. De Filippo, M.; Puglisi, S.; D’Amuri, F.; Gentili, F.; Paladini, I.; Carrafiello, G.; Maestroni, U.; Del Rio, P.; Ziglioli, F.; Pagnini, F. CT-guided percutaneous drainage of abdominopelvic collections: A pictorial essay. Radiol. Med. 2021, 126, 1561–1570. [Google Scholar] [CrossRef] [PubMed]
  72. Liu, A.; Liu, H.; Ding, X.; Wu, J.; Tian, Z.; Mao, T. Familial adenomatous polyposis associated with desmoid tumors presenting with abdominal abscess: A case report and literature review. Medicine 2021, 100, e27897. [Google Scholar] [CrossRef]
  73. Yang, T.; Liu, H.; Liao, Z.; Zhang, C.; Xiang, L.; Yang, J. Postoperative Adjuvant Radiotherapy Can Delay the Recurrence of Desmoid Tumors After R0 Resection in Certain Subgroups. Front. Surg. 2021, 8, 697793. [Google Scholar] [CrossRef] [PubMed]
  74. Sun, J.; Li, H.; Gao, J.; Li, J.; Li, M.; Zhou, Z.; Peng, Y. Performance evaluation of a deep learning image reconstruction (DLIR) algorithm in “double low” chest CTA in children: A feasibility study. Radiol. Med. 2021, 126, 1181–1188. [Google Scholar] [CrossRef] [PubMed]
  75. Schicchi, N.; Fogante, M.; Palumbo, P.; Agliata, G.; Esposto Pirani, P.; Di Cesare, E.; Giovagnoni, A. The sub-millisievert era in CTCA: The technical basis of the new radiation dose approach. Radiol. Med. 2020, 125, 1024–1039. [Google Scholar] [CrossRef] [PubMed]
  76. Palumbo, P.; Cannizzaro, E.; Bruno, F.; Schicchi, N.; Fogante, M.; Agostini, A.; De Donato, M.C.; De Cataldo, C.; Giovagnoni, A.; Barile, A.; et al. Coronary artery disease (CAD) extension-derived risk strati-fication for asymptomatic diabetic patients: Usefulness of low-dose coronary computed tomography angiography (CCTA) in detecting high-risk profile patients. Radiol. Med. 2020, 125, 1249–1259. [Google Scholar] [CrossRef]
  77. Cellini, F.; Di Franco, R.; Manfrida, S.; Borzillo, V.; Maranzano, E.; Pergolizzi, S.; Morganti, A.G.; Fusco, V.; Deodato, F.; Santarelli, M.; et al. Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: The NORMALITY model. Radiol. Med. 2021, 126, 1619–1656. [Google Scholar] [CrossRef]
  78. De Felice, F.; Boldrini, L.; Greco, C.; Nardone, V.; Salvestrini, V.; Desideri, I. ESTRO vision 2030: The young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement. Radiol. Med. 2021, 126, 1374–1376. [Google Scholar] [CrossRef]
  79. Bellardita, L.; Colciago, R.R.; Frasca, S.; De Santis, M.C.; Gay, S.; Palorini, F.; La Rocca, E.; Valdagni, R.; Rancati, T.; Lozza, L. Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment: Analysis of the Italian branch of the REQUITE project. Radiol. Med. 2021, 126, 1366–1373. [Google Scholar] [CrossRef]
  80. Braschi-Amirfarzan, M.; Keraliya, A.R.; Krajewski, K.M.; Tirumani, S.H.; Shinagare, A.B.; Hornick, J.; Baldini, E.H.; George, S.; Ramaiya, N.H.; Jagannathan, J.P. Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists. RadioGraphics 2016, 36, 767–782. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  81. Chiarilli, M.G.; Pizzi, A.D.; Mastrodicasa, D.; Febo, M.P.; Cardinali, B.; Consorte, B.; Cifaratti, A.; Panara, V.; Caulo, M.; Cannataro, G. Bone marrow magnetic resonance imaging: Physiologic and pathologic findings that radiologist should know. Radiol. Med. 2021, 126, 264–276. [Google Scholar] [CrossRef] [PubMed]
  82. Albano, D.; Cortese, M.C.; Duarte, A.; Messina, C.; Gitto, S.; Vicentin, I.; Coppola, A.; Galia, M.; Sconfienza, L.M. Predictive role of ankle MRI for tendon graft choice and surgical reconstruction. Radiol. Med. 2020, 125, 763–769. [Google Scholar] [CrossRef] [PubMed]
  83. Cobianchi Bellisari, F.; De Marino, L.; Arrigoni, F.; Mariani, S.; Bruno, F.; Palumbo, P.; De Cataldo, C.; Sgalambro, F.; Catallo, N.; Zugaro, L.; et al. T2-mapping MRI evaluation of patellofemoral cartilage in patients submitted to intra-articular platelet-rich plasma (PRP) injections. Radiol. Med. 2021, 126, 1085–1094. [Google Scholar] [CrossRef] [PubMed]
  84. Ricatti, G.; Veronese, N.; Gangai, I.; Paparella, M.; Testini, V.; Guglielmi, G. Hoffa’s fat pad thickness: A measurement method with sagittal MRI sequences. Radiol. Med. 2021, 126, 886–893. [Google Scholar] [CrossRef]
  85. Zappia, M.; Sconfienza, L.M.; Guarino, S.; Tumminello, M.; Iannella, G.; Mariani, P.P. Meniscal ramp lesions: Diagnostic performance of MRI with arthroscopy as reference standard. Radiol. Med. 2021, 126, 1106–1116. [Google Scholar] [CrossRef]
  86. Berardo, S.; Sukhovei, L.; Andorno, S.; Carriero, A.; Stecco, A. Quantitative bone marrow magnetic resonance imaging through apparent diffusion coefficient and fat fraction in multiple myeloma patients. Radiol. Med. 2021, 126, 445–452. [Google Scholar] [CrossRef]
  87. Orsatti, G.; Zucchetta, P.; Varotto, A.; Crimì, F.; Weber, M.; Cecchin, D.; Bisogno, G.; Spimpolo, A.; Giraudo, C.; Stramare, R. Volumetric histograms-based analysis of apparent diffusion coefficients and standard uptake values for the assessment of pediatric sarcoma at staging: Preliminary results of a PET/MRI study. Radiol. Med. 2021, 126, 878–885. [Google Scholar] [CrossRef]
  88. Lian, S.; Zhang, C.; Chi, J.; Huang, Y.; Shi, F.; Xie, C. Differentiation between nasopharyngeal carcinoma and lymphoma at the primary site using whole-tumor histogram analysis of apparent diffusion coefficient maps. Radiol. Med. 2020, 125, 647–653. [Google Scholar] [CrossRef]
  89. Pietragalla, M.; Nardi, C.; Bonasera, L.; Mungai, F.; Taverna, C.; Novelli, L.; De Renzis, A.G.D.; Calistri, L.; Tomei, M.; Occhipinti, M.; et al. The role of diffusion-weighted and dynamic contrast enhancement perfusion-weighted imaging in the evaluation of salivary glands neoplasms. Radiol. Med. 2020, 125, 851–863. [Google Scholar] [CrossRef]
  90. Momeni, M.; Asadzadeh, M.; Mowla, K.; Hanafi, M.G.; Gharibvand, M.M.; Sahraeizadeh, A. Sensitivity and specificity assessment of DWI and ADC for the diagnosis of osteoporosis in postmenopausal patients. Radiol. Med. 2020, 125, 68–74. [Google Scholar] [CrossRef] [PubMed]
  91. Fornell-Perez, R.; Vivas-Escalona, V.; Aranda-Sanchez, J.; Gonzalez-Dominguez, M.C.; Rubio-Garcia, J.; Aleman-Flores, P.; Loro-Ferrer, J.F. Primary and post-chemoradiotherapy MRI detection of extramural venous invasion in rectal cancer: The role of diffusion-weighted imaging. Radiol. Med. 2020, 125, 522–530. [Google Scholar] [CrossRef] [PubMed]
  92. Zhang, A.; Song, J.; Ma, Z.; Chen, T. Combined dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging to predict neoadjuvant chemotherapy effect in FIGO stage IB2-IIA2 cervical cancers. Radiol. Med. 2020, 125, 1233–1242. [Google Scholar] [CrossRef] [PubMed]
  93. Cutolo, C.; Dell’Aversana, F.; Fusco, R.; Grazzini, G.; Chiti, G.; Simonetti, I.; Bruno, F.; Palumbo, P.; Pierpaoli, L.; Valeri, T.; et al. Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know. Diagnostics 2022, 12, 890. [Google Scholar] [CrossRef] [PubMed]
  94. Bruno, F.; Granata, V.; Bellisari, F.C.; Sgalambro, F.; Tommasino, E.; Palumbo, P.; Arrigoni, F.; Cozzi, D.; Grassi, F.; Brunese, M.C.; et al. Advanced Magnetic Resonance Imaging (MRI) Techniques: Technical Principles and Applications in Nanomedicine. Cancers 2022, 14, 1626. [Google Scholar] [CrossRef]
  95. Granata, V.; Fusco, R.; Setola, S.V.; De Muzio, F.; Aversana, F.D.; Cutolo, C.; Faggioni, L.; Miele, V.; Izzo, F.; Petrillo, A. CT-Based Radiomics Analysis to Predict Histopathological Outcomes Following Liver Resection in Colorectal Liver Metastases. Cancers 2022, 14, 1648. [Google Scholar] [CrossRef]
  96. Granata, V.; Fusco, R.; Belli, A.; Borzillo, V.; Palumbo, P.; Bruno, F.; Grassi, R.; Ottaiano, A.; Nasti, G.; Pilone, V.; et al. Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. Infect. Agents Cancer 2022, 17, 13. [Google Scholar] [CrossRef]
  97. Granata, V.; Fusco, R.; Bicchierai, G.; Cozzi, D.; Grazzini, G.; Danti, G.; De Muzio, F.; Maggialetti, N.; Smorchkova, O.; D’Elia, M.; et al. Diagnostic protocols in oncology: Workup and treatment planning. Part 1: The optimitation of CT protocol. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 6972–6994. [Google Scholar] [CrossRef]
  98. Minutoli, F.; Pergolizzi, S.; Blandino, A.; Mormina, E.; Amato, E.; Gaeta, M. Effect of granulocyte colony-stimulating factor on bone marrow: Evaluation by intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging. Radiol. Med. 2020, 125, 280–287. [Google Scholar] [CrossRef]
  99. Sun, N.N.; Ge, X.L.; Liu, X.S.; Xu, L.L. Histogram analysis of DCE-MRI for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma. Radiol. Med. 2020, 125, 165–176. [Google Scholar] [CrossRef]
  100. Granata, V.; Fusco, R.; Setola, S.V.; Castelguidone, E.D.L.D.; Camera, L.; Tafuto, S.; Avallone, A.; Belli, A.; Incollingo, P.; Palaia, R.; et al. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: The radiologist’s challenge. Radiol. Oncol. 2019, 53, 373–387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  101. Halefoglu, A.M.; Ozagari, A.A. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: Radıology-pathology correlatıon. Radiol. Med. 2021, 126, 1139–1148. [Google Scholar] [CrossRef] [PubMed]
  102. Treitl, K.M.; Ricke, J.; Baur-Melnyk, A. Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging. Skelet. Radiol. 2022, 51, 43–58. [Google Scholar] [CrossRef] [PubMed]
  103. Tsili, A.C.; Andriotis, E.; Gkeli, M.G.; Krokidis, M.; Stasinopoulou, M.; Varkarakis, I.M.; Moulopoulos, L.-A. The role of imaging in the management of renal masses. Eur. J. Radiol. 2021, 141, 109777. [Google Scholar] [CrossRef]
  104. Assadsangabi, R.; Babaei, R.; Songco, C.; Ivanovic, V.; Bobinski, M.; Chen, Y.J.; Nabavizadeh, S.A. Multimodality oncologic evaluation of superficial neck and facial lymph nodes. Radiol. Med. 2021, 126, 1074–1084. [Google Scholar] [CrossRef] [PubMed]
  105. Granata, V.; Fusco, R.; Maio, F.; Avallone, A.; Nasti, G.; Palaia, R.; Albino, V.; Grassi, R.; Izzo, F.; Petrillo, A. Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases. Infect. Agents Cancer 2019, 14, 40. [Google Scholar] [CrossRef]
  106. Agarwal, M.; van der Pol, C.B.; Patlas, M.N.; Udare, A.; Chung, A.D.; Rubino, J. Optimizing the radiologist work environment: Actionable tips to improve workplace satisfaction, efficiency, and minimize burnout. Radiol. Med. 2021, 126, 1255–1257. [Google Scholar] [CrossRef]
  107. Granata, V.; Fusco, R.; Castelguidone, E.D.L.D.; Avallone, A.; Palaia, R.; Delrio, P.; Tatangelo, F.; Botti, G.; Grassi, R.; Izzo, F.; et al. Diagnostic performance of gadoxetic acid–enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection. BMC Gastroenterol. 2019, 19, 129. [Google Scholar] [CrossRef] [Green Version]
  108. Celletti, I.; Fresilli, D.; De Vito, C.; Bononi, M.; Cardaccio, S.; Cozzolino, A.; Durante, C.; Grani, G.; Grimaldi, G.; Isidori, A.M.; et al. TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: Which has better diagnostic performance? Radiol. Med. 2021, 126, 1189–1200. [Google Scholar] [CrossRef]
  109. Granata, V.; Fusco, R.; Avallone, A.; Catalano, O.; Piccirillo, M.; Palaia, R.; Nasti, G.; Petrillo, A.; Izzo, F. A radiologist’s point of view in the presurgical and intraoperative setting of colorectal liver metastases. Future Oncol. 2018, 14, 2189–2206. [Google Scholar] [CrossRef]
  110. Spoerl, S.; Spoerl, S.; Reil, S.; Gerken, M.; Ludwig, N.; Taxis, J.; Fischer, R.; Ettl, T.; Reichert, T.E.; Spanier, G. Prognostic Value of Perineural Invasion on Survival and Recurrence in Oral Squamous Cell Carcinoma. Diagnostics 2022, 12, 1062. [Google Scholar] [CrossRef] [PubMed]
  111. Liu, M.; Liu, S.; Zhao, Q.; Cui, Y.; Chen, J.; Wang, S. Using the Indocyanine Green (ICG) Lymphography to Screen Breast Cancer Patients at High Risk for Lymphedema. Diagnostics 2022, 12, 983. [Google Scholar] [CrossRef] [PubMed]
  112. Fukui, K.; Masumoto, N.; Yokoyama, E.; Kanou, A.; Yokozaki, M.; Sasada, S.; Emi, A.; Kadoya, T.; Arihiro, K.; Okada, M. Ultrasonography Combined with Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer. Cancer Diagn. Progn. 2021, 1, 309–316. [Google Scholar] [CrossRef]
  113. Wei, T.; Lu, M.; Li, J.; Hu, Z.; Li, T.; Cheng, X.; Wang, L.; Pu, W. Comparative study on efficacy and safety of ultrasound guided transoral and transcutaneous core needle biopsy in patients with oral masses. BMC Med. Imaging 2022, 22, 65. [Google Scholar] [CrossRef]
  114. Spagnuolo, G.M.; Tierney, H.T.; Laver, N.M.; Eldeiry, L.S. A Retrospective Study of Clinicopathologic Outcomes of Nodules with Hürthle Cell Cytology and the Thyroid Nodule App (TNAPP) Ultrasound Recommendations. Endocr. Pract. 2022, 28, 593–598. [Google Scholar] [CrossRef]
  115. Mital, T.; Kamal, M.; Kumar, M.; Kumar, R.; Bhatia, P.; Singariya, G. Comparison of landmark and real-time ultrasound-guided epidural catheter placement in the pediatric population: A prospective randomized comparative trial. Anesth. Pain Med. 2021, 16, 368–376. [Google Scholar] [CrossRef] [PubMed]
  116. Sparchez, Z.; Mocan, T.; Craciun, R.; Sparchez, M.; Nolsøe, C. Contrast enhancement for ultrasound-guided interventions: When to use it and what to expect? Ultrasonography 2022, 41, 263–278. [Google Scholar] [CrossRef] [PubMed]
  117. Povoski, S.P.; Jimenez, R.E. Fibromatosis (desmoid tumor) of the breast mimicking a case of ipsilateral metachronous breast cancer. World J. Surg. Oncol. 2006, 4, 57. [Google Scholar] [CrossRef] [Green Version]
  118. Escobar, C.; Munker, R.; Thomas, J.O.; Li, B.D.; Burton, G.V. Update on desmoid tumors. Ann. Oncol. 2012, 23, 562–569. [Google Scholar] [CrossRef]
  119. Mekhail, F.G.; Montgomery, J.R.; Spicer, P.J. Imaging findings of a biopsy-proven desmoid tumor of the axilla in a young female. Radiol. Case Rep. 2022, 17, 1050–1053. [Google Scholar] [CrossRef]
  120. Wang, L.; Xu, D.; Chen, L.; Huang, P. Percutaneous ultrasound-guided radiofrequency ablation for giant desmoid tumors of the intra-abdominal cavity in a patient with Gardner syndrome. J. Cancer Res. Ther. 2021, 17, 1286–1288. [Google Scholar] [CrossRef]
  121. Izzo, F.; Palaia, R.; Albino, V.; Amore, A.; Di Giacomo, R.; Piccirillo, M.; Leongito, M.; Nasto, A.; Granata, V.; Petrillo, A.; et al. Hepatocellular carcinoma and liver metastases: Clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments. Infect. Agents Cancer 2015, 10, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  122. Granata, V.; Fusco, R.; Piccirillo, M.; Palaia, R.; Petrillo, A.; Lastoria, S.; Izzo, F. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int. J. Surg. 2015, 18, 230–236. [Google Scholar] [CrossRef] [PubMed]
  123. Barile, A. Some thoughts and greetings from the new Editor-in-Chief. Radiol. Med. 2021, 126, 3–4. [Google Scholar] [CrossRef] [PubMed]
  124. Fanelli, F.; Cannavale, A.; Chisci, E.; Citone, M.; Falcone, G.M.; Michelagnoli, S.; Miele, V. Direct percutaneous embolization of aneurysm sac: A safe and effective procedure to treat post-EVAR type II endoleaks. Radiol. Med. 2021, 126, 258–263. [Google Scholar] [CrossRef] [PubMed]
  125. Aberle, S.; Kenkel, D.; Becker, A.S.; Puippe, G.; Burger, I.; Schaefer, N.; Pfammatter, T. Outpatient Yttrium-90 microsphere radioembolization: Assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. Radiol. Med. 2020, 125, 971–980. [Google Scholar] [CrossRef] [PubMed]
  126. Kasper, B.; Baumgarten, C.; Garcia, J.; Bonvalot, S.; Haas, R.; Haller, F.; Hohenberger, P.; Penel, N.; Messiou, C.; van der Graaf, W.T.; et al. An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann. Oncol. 2017, 28, 2399–2408. [Google Scholar] [CrossRef] [PubMed]
  127. Barrow, E.; Newton, K.; Rajashanker, B.; Lee, S.; Evans, G.; Hill, J. Successful radiofrequency ablation of an anterior abdominal wall desmoid in familial adenomatous polyposis. Color. Dis. 2013, 15, e160–e163. [Google Scholar] [CrossRef] [PubMed]
  128. Cobianchi, L.; Ravetta, V.; Viera, F.T.; Filisetti, C.; Siri, B.; Segalini, E.; Dionigi, P. The challenge of extraabdominal desmoid tumour management in patients with Gardner’s syndrome: Radiofrequency ablation, a promising option. World J. Surg. Oncol. 2014, 12, 361. [Google Scholar] [CrossRef] [Green Version]
  129. Ilaslan, H.; Schils, J.; Joyce, M.; Marks, K.; Sundaram, M. Radiofrequency ablation: Another treatment option for local control of desmoid tumors. Skelet. Radiol. 2010, 39, 169–173. [Google Scholar] [CrossRef]
  130. Granata, V.; Grassi, R.; Fusco, R.; Setola, S.; Belli, A.; Piccirillo, M.; Pradella, S.; Giordano, M.; Cappabianca, S.; Brunese, L.; et al. Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients. Int. J. Environ. Res. Public Health 2021, 18, 3598. [Google Scholar] [CrossRef]
  131. Masjedi, H.; Zare, M.H.; Siahpoush, N.K.; Razavi-Ratki, S.K.; Alavi, F.; Shabani, M. European trends in radiology: Investigating factors affecting the number of examinations and the effective dose. Radiol. Med. 2020, 125, 296–305. [Google Scholar] [CrossRef] [PubMed]
  132. Abe, T.; Shinzawa, H.; Wakabayashi, H.; Aoki, M.; Sugahara, K.; Iwaba, A.; Haga, H.; Miyano, S.; Terui, Y.; Mitsuhashi, H.; et al. Value of Laparoscopic Microwave Coagulation Therapy for Hepatocellular Carcinoma in Relation to Tumor Size and Location. Endoscopy 2000, 32, 598–603. [Google Scholar] [CrossRef] [PubMed]
  133. Simo, K.A.; Sereika, S.E.; Newton, K.N.; Gerber, D.A. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: Safety and efficacy in comparison with radiofrequency ablation. J. Surg. Oncol. 2011, 104, 822–829. [Google Scholar] [CrossRef] [PubMed]
  134. Fang, C.; Cortis, K.; Yusuf, G.T.; Gregory, S.; Lewis, D.; Kane, P.; Peddu, P. Complications from percutaneous microwave ablation of liver tumours: A pictorial review. Br. J. Radiol. 2019, 92, 20180864. [Google Scholar] [CrossRef]
  135. Valentino, M.; Liberatore, M.; Maghella, F.; De Soccio, V.; De Felice, C.; Messineo, D.; Drudi, F.M. Diagnostic imaging and CEUS findings in a rare case of Desmoid-type fibromatosis. A case report. J. Ultrasound 2018, 21, 253–257. [Google Scholar] [CrossRef] [Green Version]
  136. Xu, W.; Lv, K.; Huang, Y.; Wen, Q.; Pan, M.; Huang, P. Features of ultrasound and contrast enhanced ultrasound in superficial desmoid-type fibromatosis: A series of 19 cases. Clin. Hemorheol. Microcirc. 2022, 80, 211–218. [Google Scholar] [CrossRef]
  137. Shi, Z.; Zhao, X.-M.; Jiang, J.-M.; Li, M.; Xie, L.-Z. Clinical and imaging features of desmoid tumors of the extremities. World J. Clin. Cases 2021, 9, 8710–8717. [Google Scholar] [CrossRef]
  138. Figueiredo, G.; O’Shea, A.; Neville, G.M.; Lee, S.I. Rare Mesenchymal Tumors of the Pelvis: Imaging and Pathologic Correlation. RadioGraphics 2022, 42, 143–158. [Google Scholar] [CrossRef]
  139. Lee, J.H.; Paeng, S.H.; Cho, H.J.; Kim, S.T.; Lee, W.H. Desmoid Fibromatosis in the Multifidus Muscle Misdiagnosed as Intramuscular Schwannoma by Incisional Biopsy: A Case Report. Korean J. Neurotrauma 2021, 17, 212. [Google Scholar] [CrossRef]
  140. Garcia-Ortega, D.; Martín-Tellez, K.; Cuellar-Hubbe, M.; Martínez-Said, H.; Álvarez-Cano, A.; Brener-Chaoul, M.; Alegría-Baños, J.; Martínez-Tlahuel, J. Desmoid-Type Fibromatosis. Cancers 2020, 12, 1851. [Google Scholar] [CrossRef] [PubMed]
  141. Young, J.R.; Sternbach, S.; Willinger, M.; Hutchinson, I.D.; Rosenbaum, A.J. The etiology, evaluation, and management of plantar fibromatosis. Orthop. Res. Rev. 2018, 11, 1–7. [Google Scholar] [CrossRef] [Green Version]
  142. Sabharwal, S.; Ahlawat, S.; Levin, A.S.; Meyer, C.F.; Brooks, E.; Ligon, J.; Morris, C.D. Desmoid tumor mimics local recurrence of extremity sarcoma on MRI. J. Surg. Oncol. 2020, 121, 1259–1265. [Google Scholar] [CrossRef] [PubMed]
  143. Sun, Y.-S.; Zhu, H.C.; Xu, S.X.; Li, X.T.; Guan, Z.; Li, S. MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis. Front. Oncol. 2021, 11, 615986. [Google Scholar] [CrossRef]
  144. Rampado, O.; Depaoli, A.; Marchisio, F.; Gatti, M.; Racine, D.; Ruggeri, V.; Ruggirello, I.; Darvizeh, F.; Fonio, P.; Ropolo, R. Effects of different levels of CT iterative reconstruction on low-contrast detectability and radiation dose in patients of different sizes: An anthropomorphic phantom study. Radiol. Med. 2021, 126, 55–62. [Google Scholar] [CrossRef] [PubMed]
  145. Shin, N.; Choi, J.A.; Choi, J.M.; Cho, E.S.; Kim, J.H.; Chung, J.J.; Yu, J.S. Sclerotic changes of cavernous hemangioma in the cirrhotic liver: Long-term follow-up using dynamic contrast-enhanced computed tomography. Radiol. Med. 2020, 125, 1225–1232. [Google Scholar] [CrossRef]
  146. Bottari, A.; Silipigni, S.; Carerj, M.L.; Cattafi, A.; Maimone, S.; Marino, M.A.; Mazziotti, S.; Pitrone, A.; Squadrito, G.; Ascenti, G. Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis. Radiol. Med. 2020, 125, 7–14. [Google Scholar] [CrossRef]
  147. Agostini, A.; Borgheresi, A.; Mari, A.; Floridi, C.; Bruno, F.; Carotti, M.; Schicchi, N.; Barile, A.; Maggi, S.; Giovagnoni, A. Dual-energy CT: Theoretical principles and clinical applications. Radiol. Med. 2019, 124, 1281–1295. [Google Scholar] [CrossRef]
  148. Okamura, T.; Yamada, Y.; Yamada, M.; Yamazaki, A.; Shiraga, N.; Jinzaki, M. Image quality of virtual monochromatic images obtained using 320-detector row CT: A phantom study evaluating the effects of iterative reconstruction and body size. Eur. J. Radiol. 2017, 95, 212–221. [Google Scholar] [CrossRef]
  149. Megibow, A.J. Clinical abdominal dual-energy CT: 15 years later. Abdom. Radiol. 2020, 45, 1198–1201. [Google Scholar] [CrossRef]
  150. Mandel, J.E.; Kim, D.; Yarmohammadi, H.; Ziv, E.; Keohan, M.L.; D’Angelo, S.P.; Gounder, M.M.; Whiting, K.; Qin, L.-X.; Singer, S.; et al. Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Ann. Surg. Oncol. 2022, 29, 640–648. [Google Scholar] [CrossRef] [PubMed]
  151. Tremblay, K.R.; Lea, W.B.; Neilson, J.C.; King, D.M.; Tutton, S.M. Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. J. Surg. Oncol. 2019, 120, 366–375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  152. Schmitz, J.J.; Schmit, G.D.; Atwell, T.D.; Callstrom, M.R.; Kurup, A.N.; Weisbrod, A.J.; Morris, J.M. Percutaneous Cryoablation of Extraabdominal Desmoid Tumors: A 10-Year Experience. Am. J. Roentgenol. 2016, 207, 190–195. [Google Scholar] [CrossRef] [PubMed]
  153. Granata, V.; Fusco, R.; Catalano, O.; Guarino, B.; Granata, F.; Tatangelo, F.; Avallone, A.; Piccirillo, M.; Palaia, R.; Izzo, F.; et al. Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: Correlation with histologic grade. Oncotarget 2016, 7, 79357–79364. [Google Scholar] [CrossRef] [Green Version]
  154. Granata, V.; Fusco, R.; Catalano, O.; Filice, S.; Amato, D.M.; Nasti, G.; Avallone, A.; Izzo, F.; Petrillo, A. Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. PLoS ONE 2015, 10, e0142876. [Google Scholar] [CrossRef]
  155. Jensen, J.H.; Helpern, J.A. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed. 2010, 23, 698–710. [Google Scholar] [CrossRef]
  156. Rosenkrantz, A.B.; Padhani, A.R.; Chenevert, T.L.; Koh, D.-M.; Msc, F.D.K.; Taouli, B.; Le Bihan, D. Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. J. Magn. Reson. Imaging 2015, 42, 1190–1202. [Google Scholar] [CrossRef] [Green Version]
  157. Crimì, F.; Capelli, G.; Spolverato, G.; Bao, Q.R.; Florio, A.; Rossi, S.M.; Cecchin, D.; Albertoni, L.; Campi, C.; Pucciarelli, S.; et al. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC). Radiol. Med. 2020, 125, 1216–1224. [Google Scholar] [CrossRef]
  158. Santone, A.; Brunese, M.C.; Donnarumma, F.; Guerriero, P.; Mercaldo, F.; Reginelli, A.; Miele, V.; Giovagnoni, A.; Brunese, L. Radiomic features for prostate cancer grade detection through formal verification. Radiol. Med. 2021, 126, 688–697. [Google Scholar] [CrossRef]
  159. Cusumano, D.; Meijer, G.; Lenkowicz, J.; Chiloiro, G.; Boldrini, L.; Masciocchi, C.; Dinapoli, N.; Gatta, R.; Casà, C.; Damiani, A.; et al. A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer. Radiol. Med. 2021, 126, 421–429. [Google Scholar] [CrossRef]
  160. Nazari, M.; Shiri, I.; Hajianfar, G.; Oveisi, N.; Abdollahi, H.; Deevband, M.R.; Oveisi, M.; Zaidi, H. Noninvasive Fuhrman grading of clear cell renal cell carcinoma using computed tomography radiomic features and machine learning. Radiol. Med. 2020, 125, 754–762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  161. Moustafa, A.F.; Eldaly, M.M.; Zeitoun, R.; Shokry, A. Is MRI diffusion-weighted imaging a reliable tool for the diagnosis and post-therapeutic follow-up of extremity soft tissue neoplasms? Indian J. Radiol. Imaging 2019, 29, 378–385. [Google Scholar] [CrossRef] [PubMed]
  162. Bhandari, S.; Sinha, A.; Tam, E.; Stirling, J.J.; Simcock, I.; Clark, S.; Goh, V. Diffusion tensor imaging (DTI) of desmoid tumours in familial adenomatous polyposis: Initial experience. Eur. J. Radiol. 2012, 81, 3646–3651. [Google Scholar] [CrossRef]
  163. Oka, K.; Yakushiji, T.; Sato, H.; Fujimoto, T.; Hirai, T.; Yamashita, Y.; Mizuta, H. Usefulness of diffusion-weighted imaging for differentiating between desmoid tumors and malignant soft tissue tumors. J. Magn. Reson. Imaging 2011, 33, 189–193. [Google Scholar] [CrossRef] [PubMed]
  164. Petralia, G.; Summers, P.E.; Agostini, A.; Ambrosini, R.; Cianci, R.; Cristel, G.; Calistri, L.; Colagrande, S. Dynamic contrast-enhanced MRI in oncology: How we do it. Radiol. Med. 2020, 125, 1288–1300. [Google Scholar] [CrossRef] [PubMed]
  165. Fusco, R.; Granata, V.; Sansone, M.; Rega, D.; Delrio, P.; Tatangelo, F.; Romano, C.; Avallone, A.; Pupo, D.; Giordano, M.; et al. Validation of the standardized index of shape tool to analyze DCE-MRI data in the assessment of neo-adjuvant therapy in locally advanced rectal cancer. Radiol. Med. 2021, 126, 1044–1054. [Google Scholar] [CrossRef] [PubMed]
  166. Petrillo, A.; Fusco, R.; Petrillo, M.; Granata, V.; Delrio, P.; Bianco, F.; Pecori, B.; Botti, G.; Tatangelo, F.; Caracò, C.; et al. Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile. Oncotarget 2017, 8, 8143–8153. [Google Scholar] [CrossRef] [Green Version]
  167. Rega, D.; Pace, U.; Scala, D.; Chiodini, P.; Granata, V.; Bucci, A.F.; Pecori, B.; DelRio, P. Treatment of splenic flexure colon cancer: A comparison of three different surgical procedures: Experience of a high volume cancer center. Sci. Rep. 2019, 9, 10953. [Google Scholar] [CrossRef] [Green Version]
  168. Fusco, R.; Sansone, M.; Granata, V.; Grimm, R.; Pace, U.; Delrio, P.; Tatangelo, F.; Botti, G.; Avallone, A.; Pecori, B.; et al. Diffusion and perfusion MR parameters to assess preoperative short-course radiotherapy response in locally advanced rectal cancer: A comparative explorative study among Standardized Index of Shape by DCE-MRI, intravoxel incoherent motion- and diffusion kurtosis imaging-derived parameters. Abdom. Radiol. 2019, 44, 3683–3700. [Google Scholar] [CrossRef]
  169. Banerji, A.; Naish, J.H.; Watson, Y.; Jayson, G.C.; Buonaccorsi, G.A.; Parker, G.J. DCE- MRI model selection for investigating dis ruption of microvascular function in livers with metastatic disease. J. Magn. Reson. Imaging 2012, 35, 196–203. [Google Scholar] [CrossRef]
  170. Khalifa, F.; Soliman, A.; El-Baz, A.; El-Ghar, M.A.; El-Diasty, T.; Gimel’Farb, G.; Ouseph, R.; Dwyer, A.C. Models and methods for analyzing DCE-MRI: A review. Med. Phys. 2014, 41, 124301. [Google Scholar] [CrossRef] [PubMed]
  171. Mungai, F.; Verrone, G.B.; Bonasera, L.; Bicci, E.; Pietragalla, M.; Nardi, C.; Berti, V.; Mazzoni, L.N.; Miele, V. Imaging biomarkers in the diagnosis of salivary gland tumors: The value of lesion/parenchyma ratio of perfusion-MR pharmacokinetic parameters. Radiol. Med. 2021, 126, 1345–1355. [Google Scholar] [CrossRef]
  172. Russo, L.; Gui, B.; Miccò, M.; Panico, C.; De Vincenzo, R.; Fanfani, F.; Scambia, G.; Manfredi, R. The role of MRI in cervical cancer  > 2 cm (FIGO stage IB2-IIA1) conservatively treated with neoadjuvant chemotherapy followed by conization: A pilot study. Radiol. Med. 2021, 126, 1055–1063. [Google Scholar] [CrossRef] [PubMed]
  173. Wang, Y.; Wang, W.; Tang, J. Ultrasound-guided high intensity focused ultrasound treatment for extra-abdominal desmoid tumours: Preliminary results. Int. J. Hyperth. 2011, 27, 648–653. [Google Scholar] [CrossRef]
  174. Ghanouni, P.; Dobrotwir, A.; Bazzocchi, A.; Bucknor, M.; Bitton, R.; Rosenberg, J.; Avedian, R. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: A retrospective multicenter study. Eur. Radiol. 2017, 27, 732–740. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  175. Zhao, W.-P.; Han, Z.-Y.; Zhang, J.; Yu, X.-L.; Cheng, Z.-G.; Zhou, X.; Liang, P. Early experience: High-intensity focused ultrasound treatment for intra-abdominal aggressive fibromatosis of failure in surgery. Br. J. Radiol. 2016, 89, 20151026. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  176. Shi, Y.; Huang, Y.; Zhou, M.; Ying, X.; Hu, X. High-intensity focused ultrasound treatment for intra-abdominal desmoid tumors: A report of four cases. J. Med. Ultrason. 2016, 43, 279–284. [Google Scholar] [CrossRef]
  177. Najafi, A.; Fuchs, B.; Binkert, C.A. Mid-term results of MR-guided high-intensity focused ultrasound treatment for relapsing superficial desmoids. Int. J. Hyperth. 2019, 36, 537–541. [Google Scholar] [CrossRef] [Green Version]
  178. Griffin, M.O.; Kulkarni, N.M.; O’Connor, S.D.; Sudakoff, G.S.; Lea, W.B.; Tutton, S.M. Magnetic resonance-guided focused ultrasound: A brief review with emphasis on the treatment of extra-abdominal desmoid tumors. Ultrasound Q. 2019, 35, 346–354. [Google Scholar] [CrossRef]
  179. Avedian, R.S.; Bitton, R.; Gold, G.; Butts-Pauly, K.; Ghanouni, P. Is MR-guided high-intensity focused ultrasound a feasible treatment modality for desmoid tumors? Clin. Orthop. Relat. Res. 2016, 474, 697–704. [Google Scholar] [CrossRef] [Green Version]
  180. Zhang, R.; Chen, J.-Y.; Zhang, L.; Li, K.-Q.; Xiao, Z.-B.; Mo, S.-J.; Chen, L.; Chen, W.-Z. The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors. Int. J. Hyperth. 2021, 38, 89–95. [Google Scholar] [CrossRef] [PubMed]
  181. Bashir, U.; Moskovic, E.; Strauss, D.; Hayes, A.; Thway, K.; Pope, R.; Messiou, C. Soft-tissue masses in the abdominal wall. Clin. Radiol. 2014, 69, e422–e431. [Google Scholar] [CrossRef] [PubMed]
  182. Masciocchi, C.; Lanni, G.; Conti, L.; Conchiglia, A.; Fascetti, E.; Flamini, S.; Coletti, G.; Barile, A. Soft-tissue inflammatory myofibroblastic tumors (IMTs) of the limbs: Potential and limits of diagnostic imaging. Skelet. Radiol. 2012, 41, 643–649. [Google Scholar] [CrossRef] [PubMed]
  183. Masciocchi, C.; Sparvoli, L.; Barile, A. Diagnostic imaging of malignant cartilage tumors. Eur. J. Radiol. 1998, 27, S86–S90. [Google Scholar] [CrossRef]
  184. Barile, A.; Sabatini, M.; Iannessi, F.; Di Cesare, E.; Splendiani, A.; Calvisi, V.; Masciocchi, C. Pigmented villonodular synovitis (PVNS) of the knee joint: Magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled. Radiol. Med. 2004, 107, 356–366. [Google Scholar]
Figure 1. (a,b) CT assessment (arrow) of aggressive fibromatosis; the arrow shows lesion in axial; (c) MPR coronal plane of portal phase of contrast study. The lesion enhancement is mild to moderate with involvement of intestinal loops.
Figure 1. (a,b) CT assessment (arrow) of aggressive fibromatosis; the arrow shows lesion in axial; (c) MPR coronal plane of portal phase of contrast study. The lesion enhancement is mild to moderate with involvement of intestinal loops.
Jpm 12 01153 g001
Figure 2. CT assessment (arrow) of mesenteric DT (a) in portal phase of contrast study. The lesion enhancement is mild to moderate. The 18-FDG (b) assessment (arrow) with moderate uptake. Surgical sample (c).
Figure 2. CT assessment (arrow) of mesenteric DT (a) in portal phase of contrast study. The lesion enhancement is mild to moderate. The 18-FDG (b) assessment (arrow) with moderate uptake. Surgical sample (c).
Jpm 12 01153 g002
Figure 3. Axial (a) and MPR coronal (b) CT assessment of aggressive fibromatosis (arrow) in portal phase of contrast study. The lesion shows mild enhancement and involvement of blood vessels.
Figure 3. Axial (a) and MPR coronal (b) CT assessment of aggressive fibromatosis (arrow) in portal phase of contrast study. The lesion shows mild enhancement and involvement of blood vessels.
Jpm 12 01153 g003
Figure 4. Aggressive fibromatosis of the shoulder within the muscular and fascial planes of the supraspinatus and deltoid muscles depicted (arrows) on axial T2 (a) and T1 (b,c) sequences and after gadolinium (df).
Figure 4. Aggressive fibromatosis of the shoulder within the muscular and fascial planes of the supraspinatus and deltoid muscles depicted (arrows) on axial T2 (a) and T1 (b,c) sequences and after gadolinium (df).
Jpm 12 01153 g004
Figure 5. The same patient of Figure 4, treated by CT-guided cryoablation (probes and ice-ball within the lesion in (a); the follow-up control after 6 months depicts evident volumetric and enhancement reduction (arrows) of the lesion (b,c).
Figure 5. The same patient of Figure 4, treated by CT-guided cryoablation (probes and ice-ball within the lesion in (a); the follow-up control after 6 months depicts evident volumetric and enhancement reduction (arrows) of the lesion (b,c).
Jpm 12 01153 g005
Figure 6. Desmoid of the anterior abdominal wall. MRI axial slices in T2 (a), T1 (b), and gadolinium-enhanced T1 (c) sequences. A nodular lesion is evident within the muscular and fascial planes of the internal and external oblique muscles (arrow).
Figure 6. Desmoid of the anterior abdominal wall. MRI axial slices in T2 (a), T1 (b), and gadolinium-enhanced T1 (c) sequences. A nodular lesion is evident within the muscular and fascial planes of the internal and external oblique muscles (arrow).
Jpm 12 01153 g006
Figure 7. Ileal Gist (arrow) in CT portal phase of contrast study ((a) axial plane; (b) MPR sagittal plane). The lesion shows moderate enhancement with central necrosis.
Figure 7. Ileal Gist (arrow) in CT portal phase of contrast study ((a) axial plane; (b) MPR sagittal plane). The lesion shows moderate enhancement with central necrosis.
Jpm 12 01153 g007
Figure 8. MPR coronal (a) and axial CT (b) assessment (portal phase of contrast study) of Sigmoid Lymphoma (arrow). The sigma has thickened walls with inhomogeneous contrast enhancement.
Figure 8. MPR coronal (a) and axial CT (b) assessment (portal phase of contrast study) of Sigmoid Lymphoma (arrow). The sigma has thickened walls with inhomogeneous contrast enhancement.
Jpm 12 01153 g008
Figure 9. Duodenal carcinoma (arrow) in MPR coronal plane (a,b) of CT assessment during portal phase of contrast study. The duodenum has thickened walls with inhomogeneous contrast enhancement.
Figure 9. Duodenal carcinoma (arrow) in MPR coronal plane (a,b) of CT assessment during portal phase of contrast study. The duodenum has thickened walls with inhomogeneous contrast enhancement.
Jpm 12 01153 g009
Table 2. Imaging features of abdominal and extra-abdominal DTs compared to other malignancies.
Table 2. Imaging features of abdominal and extra-abdominal DTs compared to other malignancies.
TumorDesmoid Abdominal TumorOther Abdominal Malignancy Desmoid Extra-Abdominal TumorMalignant Soft Tissue Tumors
Imaging Assessment
[80,137]
The density of the lesions on CT imaging is uniform, and an enhanced scan can show uniform enhancement. Homogeneous signal is isointense in T1-W and hyperintense in T2-WInhomogeneous density on CT and signal intensity on MRI, due to necrosis and calcifications, with inhomogeneous contrast enhancement during contrast studiesCT features of desmoid tumors of the extremities exhibited a slightly low density, mild enhancement, unclear boundary and uneven enhancement after contrast administration. Their imaging features on MRI were a round or fusiform shape, unclear boundaries, uniform signal, uneven enhancement, “tree root” or “claw” infiltration and invasion of the neurovascular bundlesInhomogeneous density on CT and long T1 and long T2 signals, T2 signal intensity higher than that of fat on MRI.
Calcification or cystic necrosis
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Simonetti, I.; Bruno, F.; Fusco, R.; Cutolo, C.; Setola, S.V.; Patrone, R.; Masciocchi, C.; Palumbo, P.; Arrigoni, F.; Picone, C.; et al. Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams. J. Pers. Med. 2022, 12, 1153. https://doi.org/10.3390/jpm12071153

AMA Style

Simonetti I, Bruno F, Fusco R, Cutolo C, Setola SV, Patrone R, Masciocchi C, Palumbo P, Arrigoni F, Picone C, et al. Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams. Journal of Personalized Medicine. 2022; 12(7):1153. https://doi.org/10.3390/jpm12071153

Chicago/Turabian Style

Simonetti, Igino, Federico Bruno, Roberta Fusco, Carmen Cutolo, Sergio Venanzio Setola, Renato Patrone, Carlo Masciocchi, Pierpaolo Palumbo, Francesco Arrigoni, Carmine Picone, and et al. 2022. "Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams" Journal of Personalized Medicine 12, no. 7: 1153. https://doi.org/10.3390/jpm12071153

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop